0001116463-24-000012 | 10-K | XBRL Viewer

Print Document View Excel Document

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income tax refunds	$ (4,900)
Income taxes paid		$ 9,400	$ 13,700
Write-offs against allowance for doubtful accounts	700	2,300	100
Accruals for purchases of property and equipment	200	200	8,200
Cash and cash equivalents	290,407	83,980
Fair value of plan assets	800	700
Deferred revenue, current	1,200	1,500
Deferred revenue, noncurrent	400	700
Advertising expenses	1,600	4,800	5,100
Net foreign exchange (losses) gains	(100)	1,600	(700)
Inventories	47,614	95,704
Accounts payable	13,151	38,020
COST OF PRODUCTS AND SERVICES SOLD	233,820	239,041	116,074
Stockholders' equity	430,671	364,425	$ 380,533	$ 398,571
Revision of Prior Period, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Inventories		500
Accounts payable		1,300
COST OF PRODUCTS AND SERVICES SOLD		800
Stockholders' equity		800
Level I Instruments
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	71,700
Money Market Fund
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 112,700	$ 1,700
Common Stock Options Unvested Restricted Stock and Unvested Performance Units
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation (in shares)	1,778	436	769
Customer \| Accounts Receivable \| Customer Concentration Risk
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk	40.00%	57.00%
Customer \| Net Consolidated Revenue \| Customer Concentration Risk
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk	63.00%	58.00%
Cost of products and services sold
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Employee retention credit		$ 2,500
Research and development
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Employee retention credit		1,100
Sales and marketing
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Employee retention credit		900
General and administrative
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Employee retention credit		1,200
Buildings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	20 years
Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Amortization Period (Years)	5 years
Contract with customer payment terms	30 days
Minimum \| Computer equipment and software
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum \| Machinery and equipment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum \| Furniture and fixtures
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Amortization Period (Years)	15 years
Contract with customer payment terms	120 days
Sales commissions amortization period	1 year
Maximum \| Computer equipment and software
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum \| Machinery and equipment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum \| Furniture and fixtures
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Internal Revenue Service (IRS) \| Other Current Assets
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Amount due from Internal Revenue Services	$ 5,700	$ 5,700

Subsequent Events - Additional Information (Detail) - Subsequent Event - Sapphiros - USD ($) $ in Millions			4 Months Ended
	Feb. 13, 2024	Jan. 02, 2024	Jun. 30, 2024
Subsequent Event [Line Items]
Investment in unconsolidated entity	$ 18.3	$ 10.0
Future investment commitments			$ 1.7

Income Taxes - Components of Total Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets (liabilities):
Net operating loss carryforwards	$ 28,014	$ 39,783
Inventories	2,654	4,504
Capitalized research and development costs	3,897	6,505
Accruals and reserves currently not deductible	3,324	2,799
Acquired intangible assets	(164)	(2,641)
Depreciation and amortization	(3,567)	(6,227)
Right-of-use assets	(3,010)	(2,775)
Lease liabilities	3,173	2,990
Stock-based compensation	3,467	3,032
Tax credit carryforwards	3,326	4,509
Net deferred tax asset	41,114	52,479
Valuation allowance	(41,668)	(52,887)
Net deferred tax liability	$ (554)	$ (408)

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
NET REVENUES:
Total revenue	$ 405,472	$ 387,479	$ 233,674
COST OF PRODUCTS AND SERVICES SOLD	233,820	239,041	116,074
Gross profit	171,652	148,438	117,600
OPERATING EXPENSES:
Research and development	33,728	36,237	34,170
Sales and marketing	36,319	49,238	44,751
General and administrative	58,191	68,206	50,328
Loss on impairments	10,829	17,101	0
Change in the estimated fair value of acquisition-related contingent consideration	(99)	(188)	(1,485)
Total operating expenses	138,968	170,594	127,764
Operating income (loss)	32,684	(22,156)	(10,164)
OTHER INCOME	23,574	6,481	872
Income (loss) before income taxes	56,258	(15,675)	(9,292)
INCOME TAX EXPENSE	2,603	1,458	13,706
NET INCOME (LOSS)	$ 53,655	$ (17,133)	$ (22,998)
INCOME (LOSS) PER SHARE:
Basic earnings per share (in US dollars per share)	$ 0.73	$ (0.24)	$ (0.32)
Diluted earnings per share (in US dollars per share)	$ 0.72	$ (0.24)	$ (0.32)
SHARES USED IN COMPUTING INCOME (LOSS) PER SHARE:
Basic weighted average number of shares outstanding (in shares)	73,348	72,505	71,981
Diluted weighted average number of shares outstanding (in shares)	74,389	72,505	71,981
Products and services
NET REVENUES:
Total revenue	$ 402,222	$ 378,047	$ 226,897
Other
NET REVENUES:
Total revenue	$ 3,250	$ 9,432	$ 6,777

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

GOODWILL AND OTHER INTANGIBLE ASSETS:

Changes in goodwill are as follows:


	December 31,
	2023		2022
Balance as of January 1	$	35,104	$	40,279
Impairment	—		(3,604)
Change related to foreign currency translation	592		(1,571)
Balance as of December 31	$	35,696	$	35,104

On July 31, 2023, the Company performed a quantitative goodwill impairment test which concluded that the carrying value of its reporting units were below fair value indicating there was no impairment. The Company performed a quantitative goodwill impairment test due to the depressed market price of the Company's common stock and concluded no impairment of goodwill.

During the second quarter of 2022, the Company determined that a triggering event occurred in relation to the depressed market price of the Company's common stock and corresponding decline in the Company's market capitalization. As a

result, the Company performed an interim quantitative goodwill impairment test and concluded that the carrying value of the Company's Diagnostics reporting unit exceeded its estimated fair value and the goodwill balance for that segment was fully impaired. The Company recognized a pre-tax impairment charge of $3.6 million during the year ended December 31, 2022, which is reported in loss on impairments in the Company's consolidated statement of operations.

Intangible assets consist of the following:


		December 31, 2023
	Amortization Period (Years)	Gross		Accumulated Amortization		Net
Customer relationships	10	$	11,629	$	(11,629)	$	—
Patents and product rights	5	7,673		(7,102)		571
Developed technology	7-10	10,926		(10,926)		—
Trade names	5-15	4,626		(3,991)		635
		$	34,854	$	(33,649)	$	1,206


		December 31, 2022
	Amortization Period (Years)	Gross		Accumulated Amortization		Net
Customer relationships	10	$	14,286	$	(11,011)	$	3,275
Patents and product rights	5	7,620		(6,615)		1,005
Developed technology	7-10	15,478		(9,940)		5,538
Trade names	5-15	5,387		(3,511)		1,876
		$	42,771	$	(31,077)	$	11,694

During the third quarter of 2023, the Company identified a triggering event to test for the recoverability of intangible assets given the decline in the Company's market capitalization leading up to and as of its annual goodwill impairment testing date. The Company performed an undiscounted cash flow analysis and determined the carrying value of the developed technology, trade names, and customer relationships intangible assets could not be recovered through the sum of the undiscounted future cash flows. The Company used an income approach to determine the fair value of the developed technology and customer relationships intangible assets and the relief from royalty method for the trade names. As a result of this analysis, the Company determined the intangible assets associated with Diversigen and Novosanis were impaired as the fair value of the developed technology, trade names, and customer relationships did not exceed their carrying value. The Company recognized a pre-tax impairment charge of $6.2 million during the year ended December 31, 2023, which is reported in loss on impairments in the Company's consolidated statement of operations.

During the fourth quarter of 2023, the Company determined that its remaining developed technology intangible asset was fully impaired. As a result of failed stability studies, the Company decided to no longer pursue the technology. The Company recognized a pre-tax impairment charge of $2.4 million during the year ended December 31, 2023, which is reported in loss on impairments in the Company's consolidated statement of operations.

Amortization expense for 2023, 2022, and 2021 was $2.0 million, $2.3 million, and $3.3 million, respectively.

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:


2024	$	679
2025	314
2026	213
2027	—
2028	—
Beyond	—
	$	1,206

Retirement Plans - Additional Information (Detail)	12 Months Ended
Retirement Plans - Additional Information (Detail)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 CAD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	$ 4,000
Contributed to plan, net of forfeitures	1,600,000		$ 1,800,000	$ 1,300,000
Value of the assets associated with the plan	800,000		700,000
Total obligation under plan	800,000		700,000
RRSP \| DNA Genotek
Defined Benefit Plan Disclosure [Line Items]
Employee contributions		$ 4,000
Contributed to plan, net of forfeitures	$ 400,000		$ 500,000	$ 400,000

Commitments and Contingencies - Schedule of Estimate of Future Purchases (Detail) $ in Thousands	Dec. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2024	$ 3,964
2025	2,407
2026	0
2027	0
2028	0
Total	$ 6,371

Termination Benefits (Tables)

12 Months Ended

Dec. 31, 2023

Termination Benefits [Abstract]

Summary Of One-Time Termination Benefits

The expense included in the Company's consolidated statements of operations are as follows:


	For the Year Ended December 31, 2023
Cost of products and services sold	$	369
Research and development	566
Sales and marketing	1,543
General and administrative	787
Total	$	3,265

Termination Benefits - Summary of One-Time Termination Benefits (Details) - One-time Termination Benefits $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Termination Benefits [Line Items]
Termination benefits	$ 3,265
Cost of products and services sold
Termination Benefits [Line Items]
Termination benefits	369
Research and development
Termination Benefits [Line Items]
Termination benefits	566
Sales and marketing
Termination Benefits [Line Items]
Termination benefits	1,543
General and administrative
Termination Benefits [Line Items]
Termination benefits	$ 787

Government Capital Contracts - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Government capital contracts funding amount				$ 109,000
Percentage withheld under government contracts subject to validation testing	15.00%
Net revenues	$ 405,472	$ 387,479	$ 233,674
Proceeds from funding under government contract	48,669	60,331	531
Government Contract
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue in excess of guaranteed profit	12,800
Commonwealth of Pennsylvania
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from funding under government contract			500
Other Income
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net revenues	405,472	387,479	233,674
Other Income \| Government Contract
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net revenues	2,800	2,200	$ 600
Research and Development Expenses and Other Income \| Government Contract
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reimbursement of engineering cost	$ 2,000	$ 1,400

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]				Loss on impairments
COST OF PRODUCTS AND SERVICES SOLD			$ 233,820	$ 239,041	$ 116,074
Depreciation expense			17,900	11,700	$ 7,500
Service Life
Property, Plant and Equipment [Line Items]
COST OF PRODUCTS AND SERVICES SOLD	$ 500	$ 6,900
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Pre-tax asset impairment charge			$ 2,300
Machinery and equipment
Property, Plant and Equipment [Line Items]
Pre-tax asset impairment charge				$ 13,500

Goodwill and Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill [Line Items]
Pre-tax impairment charge	$ 0	$ 3,604
Amortization expense	2,000	$ 2,300	$ 3,300
Developed technology
Goodwill [Line Items]
Impairment of intangible assets (excluding goodwill)	2,400
Developed Technology, Trade Names And Customer Relationships
Goodwill [Line Items]
Impairment of intangible assets (excluding goodwill)	$ 6,200

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

+ Details

Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance as of January 1	$ 373	$ 805	$ 1,172
Additions for tax positions of prior periods	0	1	1
Reductions for tax positions of prior periods	(69)	(433)	(368)
Balance as of December 31	$ 304	$ 373	$ 805

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Schedule of Estimate of Future Purchases

The table below represents an estimate of future purchases under those agreements.


2024	$	3,964
2025	2,407
2026	—
2027	—
2028	—
	$	6,371

Leases - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Lessee Lease Description [Line Items]
Lessee operating and financing leases, period of options to terminate	1 year
Aggregate ROU asset and offsetting lease liability	$ 334	$ 117	$ 2,074
Minimum
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	1 year
Maximum
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	10 years

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Payroll and related benefits	$ 14,654	$ 14,103
Professional fees	2,827	4,685
Sales tax payable	1,245	1,519
Other	3,984	5,455
Total	$ 22,710	$ 25,762

Goodwill and Other Intangible Assets - Schedule of Changes in Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Goodwill [Roll Forward]
Beginning balance	$ 35,104	$ 40,279
Impairment	0	(3,604)
Change related to foreign currency translation	592	(1,571)
Ending balance	$ 35,696	$ 35,104

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Accrued Expenses And Other Current Liabilities

12 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES:


	December 31,
	2023		2022
Payroll and related benefits	$	14,654	$	14,103
Professional fees	2,827		4,685
Sales tax payable	1,245		1,519
Other	3,984		5,455
	$	22,710	$	25,762

Summary of Significant Accounting Policies - Summary of Changes in Accumulated Other Comprehensive Loss by Component (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 364,425
Other comprehensive gain	3,494
Ending balance	430,671
Revision of Prior Period, Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	800
Accumulated Other Comprehensive Loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(18,435)
Ending balance	(14,941)
Foreign Currency
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(18,215)
Other comprehensive gain	3,274
Ending balance	(14,941)
Marketable Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(220)
Other comprehensive gain	220
Ending balance	$ 0

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

COMMITMENTS AND CONTINGENCIES:

Purchase Commitments

As of December 31, 2023, the Company had manufacturing agreements with certain third party vendors, in which minimum purchase commitments are required. If the minimum commitments are not achieved, the Company will be required to make annual penalty payments over the next three years. Based on current forecasts, these penalties aggregate to approximately $1.0 million and are accrued for in the consolidated balance sheet. These estimated penalties can fluctuate based on changes in forecasted demand. The table below represents an estimate of future purchases under those agreements.


2024	$	3,964
2025	2,407
2026	—
2027	—
2028	—
	$	6,371

Litigation

From time to time, the Company is involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected, individually or in the aggregate, to have a material adverse effect on the Company's future financial position or results of operations.

Spectrum Patent Litigation

In June 2021, the Company filed a complaint against Spectrum Solutions, LLC (“Spectrum”) in the United States District Court for the Southern District of California alleging that certain saliva collection devices manufactured and sold by Spectrum infringe a patent held by DNAG. Spectrum filed an answer to the initial complaint, asserting that its device does not infringe the Company’s patent and that the Company’s patent is invalid. In August 2021, the Company amended its complaint to add a second patent to this litigation. Spectrum responded to the Company's amended complaint and asserted counterclaims for inequitable conduct and antitrust violations with respect to one of the patents in the litigation and subsequently filed a request for review of the second patent at the Patent and Trademark Office (“PTO”), which was granted by the PTO. The District Court issued multiple pretrial orders, resolving the infringement, antitrust, and inequitable conduct claims without trial. First, the District Court granted Spectrum’s motion for summary judgment of noninfringement, holding that Spectrum’s saliva collection devices are not “kits for collecting and preserving a biological sample,” among other rulings. The Company appealed the grant of summary judgment to the Court of Appeals on June 8, 2023. The appeal is pending, with oral argument expected in the second half of 2024. Second, the Court denied Spectrum’s motion to supplement its allegations of alleged antitrust violations, finding that if such an amendment were allowed, Spectrum’s claims would not survive a motion for summary judgment. Spectrum thereafter withdrew its antitrust and inequitable conduct counterclaims. Spectrum did not appeal the District Court's denial of its motion to amend. On February 7, 2024, the PTO issued a Final Written Decision regarding the second patent in the litigation, holding that claims 1, 3–8, 11, and 12 of U.S. Patent No. 11,002,646 B2 are unpatentable. The Company is considering its appellate options. On September 15, 2023, Spectrum filed a separate petition for inter partes review of a third patent, which DNAG did not assert in the District Court. The Company filed a preliminary patent owner response on December 28, 2023. That petition remains pending.

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
OPERATING ACTIVITIES:
Net income (loss)	$ 53,655	$ (17,133)	$ (22,998)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Stock-based compensation	10,729	11,622	7,807
Depreciation and amortization	20,936	15,308	11,658
Loss on impairments	10,829	17,101	0
Other non-cash amortization	3	228	837
Provision for credit losses	(462)	(1,032)	(253)
Unrealized foreign currency (gain) loss	103	(161)	(210)
Interest expense on finance leases	51	94	82
Deferred income taxes	102	(1,651)	1,026
Loss on sale of fixed assets	0	729	0
Change in the estimated fair value of acquisition-related contingent consideration	(99)	(188)	(1,485)
Payment of acquisition-related contingent consideration	(19)	0	(142)
Changes in assets and liabilities:
Accounts receivable	31,116	(25,162)	(6,451)
Inventories	48,228	(43,274)	(21,210)
Prepaid expenses and other assets	(2,499)	(7,091)	(8,674)
Accounts payable	(26,976)	2,634	3,234
Deferred revenue	(730)	(596)	(1,891)
Accrued expenses and other liabilities	(3,384)	1,370	3,288
Net cash provided by (used in) operating activities	141,583	(47,202)	(35,382)
INVESTING ACTIVITIES:
Purchases of short-term investments	(74,652)	(22,873)	(25,822)
Proceeds from maturities and redemptions of short-term investments	102,440	47,415	67,925
Proceeds from sale of assets	0	121	0
Purchases of property and equipment	(5,802)	(6,774)	(21,893)
Purchase of property and equipment under government contracts	(4,501)	(57,135)	(26,224)
Proceeds from funding under government contract	48,669	60,331	531
Other investing activities	0	0	(18)
Net cash provided by (used in) investing activities	66,154	21,085	(5,501)
FINANCING ACTIVITIES:
Cash payments for lease liabilities	(1,345)	(1,381)	(686)
Proceeds from exercise of stock options	269	15	246
Payment of acquisition-related contingent consideration	(46)	(208)	(264)
Repurchase of common stock	(1,901)	(2,254)	(2,113)
Net cash used in financing activities	(3,023)	(3,828)	(2,817)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	1,713	(2,837)	(340)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	206,427	(32,782)	(44,040)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	83,980	116,762	160,802
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 290,407	$ 83,980	$ 116,762

Property, Plant and Equipment - Schedule of Long-lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 58,266	$ 71,105
United States
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	48,311	60,751
Canada
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	8,777	8,526
Other regions
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 1,178	$ 1,828

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

Schedule of Income (Loss) Before Income Tax Expense (Benefit)

Income (loss) before income tax expense consists of the following:


	For the Years Ended December 31,
	2023		2022		2021
United States	$	61,671	$	(7,111)	$	(60,500)
Foreign	(5,413)		(8,564)		51,208
	$	56,258	$	(15,675)	$	(9,292)

Components of Income Tax Expense (Benefit)

The components of income tax expense (benefit) are as follows:


	For the Years Ended December 31,
	2023		2022		2021
Current
Federal	$	—	$	—	$	—
State	1,896		955		163
Foreign	605		2,154		12,517
	2,501		3,109		12,680
Deferred
Federal	13,570		(2,250)		(10,318)
State	(382)		(633)		(965)
Foreign	(1,867)		(2,617)		(151)
	11,321		(5,500)		(11,434)
Increase (decrease) in valuation allowance	(11,219)		3,849		12,460
	102		(1,651)		1,026
Total income tax expense	$	2,603	$	1,458	$	13,706

Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate

reconciliation of the statutory United States federal income tax rate to the Company's effective tax rate is as follows:


	For the Years Ended December 31,
	2023		2022		2021
Statutory U.S. federal income tax rate	21.0	%	21.0	%	21.0	%
Nondeductible executive compensation	0.5		(5.8)		(6.1)
Impact of stock-based payment awards	(0.3)		(5.1)		(3.3)
Tax effect of foreign items	(0.4)		(6.0)		(30.8)
State income taxes, net of federal benefit	2.0		(0.8)		6.8
U.S. and foreign tax credits	1.3		3.7		2.5

Nondeductible expenses and other	0.9		8.7		(4.0)

Change in valuation allowance, federal and state	(20.4)		(25.0)		(133.6)
Effective tax rate	4.6	%	(9.3)	%	(147.5)	%

Components of Total Deferred Tax Assets (Liabilities)

Significant components of the Company's deferred tax assets (liabilities) are as follows:


	December 31,
	2023		2022
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	28,014	$	39,783
Inventories	2,654		4,504
Capitalized research and development costs	3,897		6,505
Accruals and reserves currently not deductible	3,324		2,799
Acquired intangible assets	(164)		(2,641)
Depreciation and amortization	(3,567)		(6,227)
Right-of-use assets	(3,010)		(2,775)
Lease liabilities	3,173		2,990
Stock-based compensation	3,467		3,032
Tax credit carryforwards	3,326		4,509
Net deferred tax asset	41,114		52,479
Valuation allowance	(41,668)		(52,887)
Net deferred tax liability	$	(554)	$	(408)

Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits

reconciliation of the Company's unrecognized tax benefits is as follows:


	2023		2022		2021
Balance as of January 1	$	373	$	805	$	1,172
Additions for tax positions of prior periods	—		1		1
Reductions for tax positions of prior periods	(69)		(433)		(368)
Balance as of December 31	$	304	$	373	$	805

Stockholders' Equity - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants under the Stock Plan	4,581,000
Award requisite service period	3 years
Achievement period	3 years
Total compensation cost	$ 10,729,000	$ 11,622,000	$ 7,807,000
Proceeds from exercise of stock options	269,000	15,000	246,000
Income tax benefit realized from stock option exercises during period	0	0	0
Total cost of common stock purchased and retired	$ 1,901,000	$ 2,254,000	$ 2,113,000
Amount share repurchase program of common shares				$ 25,000,000
Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage	75.00%
Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage	25.00%
Share Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	0	0	0
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of the fair market value of a share granted as Stock plan price	75.00%
Granted exercise period	10 years
Vesting period	4 years
Weighted-average grant date fair value of stock options granted (in US dollars per share)	$ 3.24	$ 4.15	$ 6.14
Total compensation cost	$ 1,300,000	$ 1,500,000	$ 1,100,000
Aggregate intrinsic value of options exercised	43,000	4,000	130,000
Unrecognized compensation expense related to unvested option awards	$ 2,600,000
Expected weighted-average period for recognition of compensation expense related to unvested awards	2 years 7 months 6 days
Proceeds from exercise of stock options	$ 300,000	20,000.00	200,000
Stock Options \| Share-based Compensation Award, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Stock Options \| Share-based Compensation Award, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 7,600,000	$ 9,200,000	$ 4,100,000
Expected weighted-average period for recognition of compensation expense related to unvested awards	1 year 6 months
Unrecognized compensation expense related to unvested restricted stock awards	$ 7,700,000
Vesting of restricted shares, withholding and exercise obligations	262,000	241,000	107,000
Restricted shares of common stock, aggregate values	$ 1,400,000	$ 1,600,000	$ 1,400,000
Performance Based Restricted Stock \| Share-based Compensation Award, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Performance Based Restricted Stock \| Share-based Compensation Award, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Based Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 1,800,000	$ 900,000	$ 2,700,000
Expected weighted-average period for recognition of compensation expense related to unvested awards	1 year 10 months 24 days
Unrecognized compensation expense related to unvested restricted stock awards	$ 4,400,000
Number of shares purchased and retired	86,000	88,000	46,000
Total cost of common stock purchased and retired	$ 500,000	$ 600,000	$ 700,000
Maximum \| Performance Based Restricted Stock \| Share-based Compensation Award, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of actual performance share units granted	150.00%
Minimum \| Performance Based Restricted Stock \| Share-based Compensation Award, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of actual performance share units granted	0.00%

The Company	12 Months Ended
The Company	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	THE COMPANY: OraSure Technologies transforms health through actionable insight by powering the shift that connects people to healthcare wherever they are. In February 2023, the Company announced a corporate restructuring to combine the commercial and innovation teams across two segments, being the “Diagnostics” segment and the “Molecular Solutions” segment, into one business unit with sales, marketing, product development, and research teams covering multiple product lines. This change is intended to accelerate innovation, enhance customer experience and result in operational synergies. As a result, all products and services reside under one reporting hierarchy. The Company's product portfolio is broadly divided into diagnostics products and molecular sample management solutions. The Company's business consists of the development, manufacture, marketing and sale of simple, diagnostic products and specimen collection devices designed to detect certain infectious diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. The Company's business also includes molecular sample management solutions and molecular services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.

Government Capital Contracts

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Government Capital Contracts

GOVERNMENT CAPITAL CONTRACTS:

In September 2021, the Company entered into an agreement for $109.0 million in funding from the DOD, in coordination with the Department of Health and Human Services, to build additional manufacturing capacity in the United States for its InteliSwab® COVID-19 Rapid Tests as part of the nation’s pandemic preparedness plan. In accordance with the agreement, funding was paid to the Company based on achievement of milestones for the design, acquisition, installation, qualification and acceptance of the manufacturing equipment, as set forth in the agreement. In accordance with the milestone payment schedule, 15% of the total was not billed and funded until the completion of the final validation testing, which occurred in October 2023. The Company began making payments to vendors for the capital project during the fourth quarter of 2021. The Company began receiving funds from the DOD in January 2022 and has received $109.0 million as of December 31, 2023. In connection with the completion of the contract in the fourth quarter of 2023, all funds were received.

Activity for these capital contracts is accounted for pursuant to International Accounting Standards ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance. Funding received in relation to capital-related costs incurred for government contracts is recorded as a reduction to the cost of property, plant and equipment and reflected within investing activities in the consolidated statements of cash flows and associated unpaid liabilities and government proceeds receivable are considered non-cash changes in such balances within the operating section of the consolidated statements of cash flows.

Amounts earned for the Company's guaranteed profit which covered project management costs were recognized straight-line in other income over the term of the government contract. The Company recognized $2.8 million, $2.2 million and

$0.6 million of such income, which is reported as other income in the Company's consolidated statement of operations for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, in connection with the completion of the contract, the Company recognized $12.8 million in excess of the guaranteed profit in other income in the Company's consolidated statement of operations for the year ended December 31, 2023, which reflects the difference in overall spend compared to the firm fixed price contract amount of $109.0 million.

The DOD also reimbursed the Company for certain engineering consulting costs. These expenses are reflected in research and development expenses as incurred with the corresponding amount presented in other income. For the years ended December 31, 2023 and 2022, $2.0 million and $1.4 million was recorded in research and development expenses and other income, respectively.

Additionally, during 2021, the Company received $0.5 million in funding from the Commonwealth of Pennsylvania, acting through the Department of Community and Economic Development, for the purchase of machinery and equipment as part of an expansion of manufacturing operations in Pennsylvania. All related purchases were completed in 2021.

The balances corresponding to government contracts included in the Company's consolidated balance sheet are as follows:


	December 31,
		2022
Other current assets:
Billed receivables		$	—
Unbilled receivables		27,013
Total other current assets		27,013
Other noncurrent assets		—
Accrued expenses and other current liabilities		$	(318)

The activity corresponding to the government contracts included in the Company's consolidated statements of cash flows is as follows:


	December 31,
	2023		2022
Cost of assets, cumulative	$	86,993	$	83,359
Reduction for funding earned to date, not yet received	—		(22,497)
Reduction for funding received to date	(86,993)		(60,862)
Total property, plant and equipment, net	$	—	$	—

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Summary of Available-for-sale Securities

The following is a summary of the Company's available-for-sale securities as of December 31, 2022:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value




December 31, 2022
Guaranteed investment certificates	$	22,109	$	—	$	—	$	22,109
Corporate bonds	4,978		—		(220)		4,758
Total available-for-sale securities	$	27,087	$	—	$	(220)	$	26,867

Disaggregation of Revenue by Product and Geographic Area

Revenues by product. The following table represents total net revenues by product line:


	For the Years Ended December 31,
	2023		2022		2021
COVID-19 (1)	$	257,779	$	243,325	$	76,874
HIV	60,823		38,812		42,144
Molecular Sample Management Solutions (2)	54,274		63,342		72,603
HCV	12,871		13,369		11,783
Risk assessment testing	9,736		10,269		9,678
Molecular Services	4,474		7,296		11,840
Other product and services revenues	2,265		1,634		1,975
Net product and services revenues	402,222		378,047		226,897
Non-product and services revenues (3)	3,250		9,432		6,777
Net revenues	$	405,472	$	387,479	$	233,674

(1) Includes COVID-19 Diagnostics and COVID-19 Molecular Products.

(2) Includes Genomics, Microbiome and Novosanis product revenues.

(3) Non-product and services revenues include funded research and development contracts, royalty income and grant revenues.

The following table represents total net revenues by geographic area, based on the location of the customer:


	For the Years Ended December 31,
	2023		2022		2021
United States	$	361,660	$	350,206	$	188,383
Europe	8,111		11,536		13,799
Other regions	35,701		25,737		31,492
	$	405,472	$	387,479	$	233,674

Schedule of Earnings Per Share, Basic and Diluted

Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.


	For the Years Ended December 31,
	2023		2022		2021
Net income (loss)	$	53,655	$	(17,133)	$	(22,998)
Weighted average shares of common stock outstanding:
Basic	73,348		72,505		71,981
Dilutive effect of stock options, restricted stock, and performance stock units	1,041		—		—
Diluted	74,389		72,505		71,981
Earnings per share:
Basic	$	0.73	$	(0.24)	$	(0.32)
Diluted	$	0.72	$	(0.24)	$	(0.32)

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes in accumulated other comprehensive loss by component is listed below:


	Foreign Currency		Marketable Securities		Total
Balance as of December 31, 2022	$	(18,215)	$	(220)	$	(18,435)
Other comprehensive gain	3,274		220		3,494
Balance as of December 31, 2023	$	(14,941)	$	—	$	(14,941)

- Definition

Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

+ Details

Leases (Tables)

12 Months Ended

Dec. 31, 2023

Lessee Disclosure [Abstract]

Summary of Components of Lease Expense

The components of lease expense are as follows:


	For the Years Ended December 31,
	2023		2022		2021
Operating lease cost	$	2,407	$	2,910	$	2,226
Variable and short-term lease cost	381		521		201
Finance lease cost:
Amortization of right-of use assets	1,091		1,299		900
Interest on lease liabilities	51		94		82
Total finance lease cost	1,142		1,393		982
Total lease cost	$	3,930	$	4,824	$	3,409

Summary of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases is as follows:


	For the Years Ended December 31,
	2023		2022		2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	1,863	$	2,209	$	3,733
Operating cash flows from financing leases	51		94		82
Financing cash flows from financing leases	1,345		1,381		686
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations	4,363		3,963		6,480
Right-of-use assets obtained in exchange for finance lease obligations	334		117		2,074

Summary of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases is as follows:


	December 31,
	2023		2022














Weighted Average Remaining Lease Term
Weighted-average remaining lease term — operating leases	8.51 years		6.24 years
Weighted-average remaining lease term — finance leases	1.71 years		1.33 years

Weighted Average Discount Rate
Weighted-average discount rate — operating leases	3.71	%	4.06	%
Weighted-average discount rate — finance leases	3.45	%	3.44	%

Schedule of Minimum Lease Payments by Period Expected

As of December 31, 2023, minimum lease payments by period are expected to be as follows:


	Finance		Operating
2024	$	578	$	2,016
2025	97		2,005
2026	95		1,745
2027	45		1,559
2028	—		1,499
Thereafter	—		5,999
Total minimum lease payments	815		14,823
Less: imputed interest	(50)		(2,084)
Present value of lease liabilities	$	765	$	12,739

Stockholders' Equity - Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan (Detail) - Restricted Stock Award and Restricted Stock Units shares in Thousands	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares) \| shares	2,573
Granted (in shares) \| shares	912
Vested (in shares) \| shares	(813)
Forfeited (in shares) \| shares	(151)
Ending balance (in shares) \| shares	2,521
Issued and expected to vest (in shares) \| shares	2,518
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Beginning balance (in US dollars per share) \| $ / shares	$ 6.51
Granted (in US dollars per share) \| $ / shares	6.05
Vested (in US dollars per share) \| $ / shares	7.13
Forfeited (in US dollars per share) \| $ / shares	8.22
Ending balance (in US dollars per share) \| $ / shares	6.04
Issued and expected to vest (in US dollars per share) \| $ / shares	$ 6.04

Summary of Significant Accounting Policies - Summary Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Net income (loss)	$ 53,655	$ (17,133)	$ (22,998)
Weighted average shares of common stock outstanding:
Basic	73,348	72,505	71,981
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]
Dilutive effect of stock options, restricted stock, and performance stock units	1,041	0	0
Diluted	74,389	72,505	71,981
Earnings per share:
Basic earnings per share (in US dollars per share)	$ 0.73	$ (0.24)	$ (0.32)
Earnings per share:
Diluted earnings per share (in US dollars per share)	$ 0.72	$ (0.24)	$ (0.32)

Leases

12 Months Ended

Dec. 31, 2023

Lessee Disclosure [Abstract]

Leases

LEASES:

The Company determines whether an arrangement is a lease at inception. The Company has operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of December 31, 2023, the Company is the lessee in all lease agreements. The Company's leases have remaining lease terms of 1 to 10 years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year. The Company presents the operating right-of-use asset amortization and the change in operating lease liabilities on the other non-cash amortization line item of the consolidated statements of cash flows.

As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

The Company has lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, the Company accounts for lease components separately from non-lease components.

The components of lease expense are as follows:


	For the Years Ended December 31,
	2023		2022		2021
Operating lease cost	$	2,407	$	2,910	$	2,226
Variable and short-term lease cost	381		521		201
Finance lease cost:
Amortization of right-of use assets	1,091		1,299		900
Interest on lease liabilities	51		94		82
Total finance lease cost	1,142		1,393		982
Total lease cost	$	3,930	$	4,824	$	3,409

Supplemental cash flow information related to leases is as follows:


	For the Years Ended December 31,
	2023		2022		2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	1,863	$	2,209	$	3,733
Operating cash flows from financing leases	51		94		82
Financing cash flows from financing leases	1,345		1,381		686
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations	4,363		3,963		6,480
Right-of-use assets obtained in exchange for finance lease obligations	334		117		2,074

Supplemental balance sheet information related to leases is as follows:


	December 31,
	2023		2022














Weighted Average Remaining Lease Term
Weighted-average remaining lease term — operating leases	8.51 years		6.24 years
Weighted-average remaining lease term — finance leases	1.71 years		1.33 years

Weighted Average Discount Rate
Weighted-average discount rate — operating leases	3.71	%	4.06	%
Weighted-average discount rate — finance leases	3.45	%	3.44	%

As of December 31, 2023, minimum lease payments by period are expected to be as follows:


	Finance		Operating
2024	$	578	$	2,016
2025	97		2,005
2026	95		1,745
2027	45		1,559
2028	—		1,499
Thereafter	—		5,999
Total minimum lease payments	815		14,823
Less: imputed interest	(50)		(2,084)
Present value of lease liabilities	$	765	$	12,739

Summary of Significant Accounting Policies - Summary of Earnings by Geographic Region (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation Of Revenue [Line Items]
Net revenues	$ 405,472	$ 387,479	$ 233,674
United States
Disaggregation Of Revenue [Line Items]
Net revenues	361,660	350,206	188,383
Europe
Disaggregation Of Revenue [Line Items]
Net revenues	8,111	11,536	13,799
Other regions
Disaggregation Of Revenue [Line Items]
Net revenues	$ 35,701	$ 25,737	$ 31,492

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Termination Benefits - Additional Information (Details) $ in Millions	Dec. 31, 2023 USD ($)
Termination Benefits [Abstract]
Accrued reduction in workforce	$ 0.4
Payment of reduction in workforce	$ 2.9

Stockholders' Equity - Weighted-Average Assumptions for Fair Value Measurement (Detail)

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Share-Based Payment Arrangement [Abstract]

Risk-free interest rate

^[1]

4.23%

1.65%

0.47%

Expected dividend yield

0.00%

Expected stock price volatility

^[2]

51.00%

50.00%

Expected life of stock options (in years)

^[2]

5 years

[1]	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of the Company's stock options.
[2]	Based upon historical experience.

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2023
Audit Information [Abstract]
Auditor Name	KPMG LLP
Auditor Location	Philadelphia, PA
Auditor Firm ID	185

Income Taxes

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES:

Income (loss) before income tax expense consists of the following:


	For the Years Ended December 31,
	2023		2022		2021
United States	$	61,671	$	(7,111)	$	(60,500)
Foreign	(5,413)		(8,564)		51,208
	$	56,258	$	(15,675)	$	(9,292)

The components of income tax expense (benefit) are as follows:


	For the Years Ended December 31,
	2023		2022		2021
Current
Federal	$	—	$	—	$	—
State	1,896		955		163
Foreign	605		2,154		12,517
	2,501		3,109		12,680
Deferred
Federal	13,570		(2,250)		(10,318)
State	(382)		(633)		(965)
Foreign	(1,867)		(2,617)		(151)
	11,321		(5,500)		(11,434)
Increase (decrease) in valuation allowance	(11,219)		3,849		12,460
	102		(1,651)		1,026
Total income tax expense	$	2,603	$	1,458	$	13,706

For the years ended December 31, 2023, 2022, and 2021 the Company recorded net foreign income tax expense of $0.7 million, $0.5 million, and $13.5 million, respectively. The Company's 2022 foreign income tax expense includes $1.7 million of Canadian withholding taxes paid on the repatriation of Canadian earnings offset by a foreign income tax benefit of $1.2 million associated with the Company's Canadian subsidiary. For the years ended December 31, 2023, 2022, and 2021 the Company recorded U.S. state tax expense of $1.9 million, $1.0 million, and $0.2 million respectively.

The reconciliation of the statutory United States federal income tax rate to the Company's effective tax rate is as follows:


	For the Years Ended December 31,
	2023		2022		2021
Statutory U.S. federal income tax rate	21.0	%	21.0	%	21.0	%
Nondeductible executive compensation	0.5		(5.8)		(6.1)
Impact of stock-based payment awards	(0.3)		(5.1)		(3.3)
Tax effect of foreign items	(0.4)		(6.0)		(30.8)
State income taxes, net of federal benefit	2.0		(0.8)		6.8
U.S. and foreign tax credits	1.3		3.7		2.5

Nondeductible expenses and other	0.9		8.7		(4.0)

Change in valuation allowance, federal and state	(20.4)		(25.0)		(133.6)
Effective tax rate	4.6	%	(9.3)	%	(147.5)	%

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carryforwards. Significant components of the Company's deferred tax assets (liabilities) are as follows:


	December 31,
	2023		2022
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	28,014	$	39,783
Inventories	2,654		4,504
Capitalized research and development costs	3,897		6,505
Accruals and reserves currently not deductible	3,324		2,799
Acquired intangible assets	(164)		(2,641)
Depreciation and amortization	(3,567)		(6,227)
Right-of-use assets	(3,010)		(2,775)
Lease liabilities	3,173		2,990
Stock-based compensation	3,467		3,032
Tax credit carryforwards	3,326		4,509
Net deferred tax asset	41,114		52,479
Valuation allowance	(41,668)		(52,887)
Net deferred tax liability	$	(554)	$	(408)

In assessing the realizability of the Company's deferred tax asset, the Company considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent upon several factors, including the generation of sufficient taxable income, to realize the NOL carryforwards. In 2008, the Company established a full valuation allowance against the Company's U.S. deferred tax asset, and although the Company has achieved another year of U.S. pre-tax earnings based on a rolling three year window the Company has not achieved a level of sustained profitability that would, in the Company's judgement, support the release of the valuation allowance. Management believes the full valuation allowance is still appropriate as of December 31, 2023 and 2022. As a result, no U.S. federal income tax benefit was recorded for the years ended December 31, 2023, 2022, and 2021.

The Company's federal NOL carryforwards of $100.0 million have no expiration date.

The Tax Reform Act of 1986 contains provisions under Internal Revenue Code (“IRC”) Section 382 that limit the annual amount of federal and state NOL carryforwards that can be used in any given year in the event a significant change in ownership. The Company does not believe that there is a Section 382 limitation that will impair the Company's future ability to utilize NOLs to offset the Company's future taxable income. The Company continues to review ownership

changes on an annual basis and the Company does not believe it has had a subsequent ownership change that would impact the NOLs.

In January 2022, approximately $65.0 million was repatriated from the Company's Canadian subsidiary as a one-time event. Associated with this repatriation the Company paid $1.7 million in Canadian withholding tax which is included in the Company's foreign income tax expense within the table further above. It is still the Company's intention to continue to permanently reinvest the historical undistributed earnings of the Company's foreign subsidiary to the extent that the Company will not incur any additional tax expense associated with foreign withholding or other local tax expense on the future cash transfers. As such, deferred taxes have not been recorded on the unremitted earnings of the foreign subsidiary as of December 31, 2023.

As of December 31, 2023, the Company's gross unrecognized tax benefits totaled $0.3 million, and based upon the valuation allowance for the Company's U.S. operations, the recognition of any tax benefit would not impact the Company's effective tax rate. The Company records interest and penalties related to unrecognized tax benefits as a component of income tax expense. Interest and penalties were immaterial in 2023, 2022, and 2021. As a result of the Company's net operating loss carryforward position, the Company is subject to audit by the Internal Revenue Service since the Company's inception, as well as by several jurisdictions for the years ended September 30, 1998 through December 31, 2023.

The reconciliation of the Company's unrecognized tax benefits is as follows:


	2023		2022		2021
Balance as of January 1	$	373	$	805	$	1,172
Additions for tax positions of prior periods	—		1		1
Reductions for tax positions of prior periods	(69)		(433)		(368)
Balance as of December 31	$	304	$	373	$	805

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Transition Costs - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Transition Costs [Line Items]
Severance accrual		$ 1,600
Stock-based compensation	$ 10,729	$ 11,622	$ 7,807
Transition costs
Transition Costs [Line Items]
Stock-based compensation	$ 1,500

Leases - Schedule of Minimum Lease Payments by Period Expected (Detail) $ in Thousands	Dec. 31, 2023 USD ($)
Finance Lease Liabilities, Payments, Due [Abstract]
2024	$ 578
2025	97
2026	95
2027	45
2028	0
Thereafter	0
Total minimum lease payments	815
Less: imputed interest	(50)
Present value of lease liabilities	765
Operating Lease Liabilities, Payments Due [Abstract]
2024	2,016
2025	2,005
2026	1,745
2027	1,559
2028	1,499
Thereafter	5,999
Total minimum lease payments	14,823
Less: imputed interest	(2,084)
Present value of lease liabilities	$ 12,739

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNAG, Diversigen, and Novosanis. All intercompany transactions and balances have been eliminated. References herein to “we”, “us”, “our”, or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for property, plant and equipment, intangible assets and goodwill, as well as estimates related to taxes, contingent consideration, and performance-based compensation expense. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Employee Retention Credit

In December 2021, the Company applied for the Employee Retention Credit for payroll taxes paid in the first and second quarters of 2021 as provided by the Coronavirus Aid, Relief and Economic Security Act. The amount due from the Internal Revenue Service of $5.7 million was recorded in other current assets in the Company's consolidated balance sheet as of December 31, 2022. The amount was received in 2023. The credit is reported in the Company's consolidated statement of operations for the year ended December 31, 2021 within cost of products and services sold, research and development, sales and marketing and general and administrative costs in the amounts of $2.5 million, $1.1 million, $0.9 million, and $1.2 million, respectively.

Supplemental Cash Flow Information

The Company received income tax refunds of $4.9 million in 2023, and paid income taxes of $9.4 million and $13.7 million in 2022 and 2021, respectively.

The Company had account receivable write-offs of $0.7 million, $2.3 million, and $0.1 million in 2023, 2022, and 2021, respectively.

As of December 31, 2023, 2022 and 2021, the Company had accruals for purchases of property and equipment of $0.2 million, $0.2 million and $8.2 million, respectively.

Cash Equivalents & Short-Term Investments

The Company considers all investments in debt securities to be available-for-sale securities. These securities are comprised of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Securities with maturities ninety days or less are considered cash equivalents. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

The Company records an allowance for credit loss for the Company's available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, the Company reviews factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value, and the probability that the scheduled cash payments will continue to be made.

The Company had no available-for-sale debt securities as of December 31, 2023. The following is a summary of the Company's available-for-sale securities as of December 31, 2022:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value




December 31, 2022
Guaranteed investment certificates	$	22,109	$	—	$	—	$	22,109
Corporate bonds	4,978		—		(220)		4,758
Total available-for-sale securities	$	27,087	$	—	$	(220)	$	26,867

Fair Value of Financial Instruments

As of December 31, 2023 and 2022, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The Company had no available-for-sale debt securities as of December 31, 2023. All of the Company's available-for-sale debt securities as of December 31, 2022 are measured as Level 2 instruments. The Company's guaranteed investment certificates are measured as Level 1 instruments as of December 31, 2022.

Included in cash and cash equivalents at December 31, 2023 and 2022, was $112.7 million and $1.7 million, respectively, invested in government money market funds. These funds have investments in United States government securities and are

measured as Level 1 instruments. Included in cash and cash equivalents at December 31, 2023 was $71.7 million of guaranteed investment certificates which are also measured as Level 1 instruments.

The Company offers a nonqualified deferred compensation plan for certain eligible employees and members of the Company's Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds. The fair value of the plan assets as of December 31, 2023 and 2022 was $0.8 million and $0.7 million, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and other noncurrent assets with the same amounts included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets.

Contingent consideration obligations are measured as Level 3 liabilities due to the unobservable inputs that are required to measure the fair value of these obligations. The Company had no contingent consideration obligations outstanding as of December 31, 2023.

Accounts Receivable

Accounts receivable has been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of the Company's customers and the Company's historical experience related to write-offs.

Inventories

Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of the Company's inventories are subject to expiration dating, which can be extended in certain circumstances. The Company continually evaluates quantities on hand and the carrying value of the Company's inventories to determine the need for net realizable value adjustments for excess and obsolete inventories, based primarily on prior experience with consideration of expected changes in the business and estimated forecasts of product sales. The Company reserves for unidentified scrap or spoilage based on historical write-off rates. The Company also considers items identified through specific identification procedures in assessing the adequacy of the Company's reserve. Although the Company makes every effort to ensure the accuracy of expected changes in the business and of its forecasts of future product demand, any significant unanticipated changes in demand could have a significant impact on the carrying value of its inventories and reported operating results

Property, Plant and Equipment

Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are typically depreciated over twenty years, while computer equipment and software, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations.

Intangible Assets

Intangible assets consist of customer relationships, patents and product rights, acquired technology and trade names. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years.

Impairment of Long-Lived Assets

Long-lived assets, which include property, plant and equipment and definite-lived intangible assets, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company assesses the recoverability of the Company's long-lived assets by determining

whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of the assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect the Company's assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time. See Notes 5 and 6 for discussion of property, plant and equipment and intangible asset impairments, respectively, recorded for the year ended December 31, 2023.

Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Goodwill is not amortized but rather is tested annually for impairment or more frequently if the Company believes that indicators of impairment exist. Current generally accepted accounting principles permit the Company to make a qualitative evaluation about the likelihood of goodwill impairment. If the Company concludes that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then the Company would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

The Company has historically performed an annual goodwill impairment assessment as of July 31. On July 31, 2023, the Company performed a quantitative goodwill impairment test which concluded that the carrying value was below fair value indicating there was no impairment. During the three months ended December 31, 2023, the Company changed the date of its the annual impairment assessment to November 30, to better align with the Company's annual forecasting process. As of November, 30, 2023, the Company performed a qualitative analysis that concluded it was more likely than not that the fair value of the Company's reporting units is greater than their carrying value.

A more frequent evaluation is performed if an event occurs or circumstances change between annual tests that could more likely than not reduce the fair value of a reporting unit below its carrying amount.

Revenues

Revenue

Product sales. Revenue from product sales is recognized upon transfer of control of a product to a customer based on an amount that reflects the consideration the Company is entitled to, net of allowances for any discounts or rebates.

The Company generally does not grant product return rights to its customers, except for warranty returns and return rights on sales of the Company's OraQuick® In-Home HIV test to retail trade customers, and InteliSwab® products to retail trade and certain other customers.

Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, the Company expenses warranty returns as incurred.

The Company records shipping and handling charges billed to the Company's customers as product revenue and the related expense as cost of products sold.

Service revenues. Service revenues represent microbiome laboratory testing and analytical services. The Company recognizes revenues when the Company satisfies its performance obligations for services rendered.

Arrangements with multiple-performance obligations. In arrangements involving more than one performance obligation, which largely applies to the Company's service revenue stream, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on their respective relative stand-alone selling price. The estimated selling price of each performance obligation is determined using an observable cost plus margin approach. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred for the related goods or services or when the performance obligation has been satisfied.

Other revenues. Other revenues consist primarily of royalty income and funding from grants of research and development efforts. For the year ended December 31, 2021, other revenue also included cost reimbursements under a charitable support

agreement which ended in June 2021. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Research and development grant revenue is recognized pursuant to International Accounting Standard 20, Accounting for Government Grants and Disclosure of Government Assistance ("IAS 20"). The expenses are recorded in research and development expense and the reimbursements are recorded in other revenue. Funding of research and development efforts and charitable support reimbursements are recorded as the activities are performed in accordance with the respective agreements.

Deferred revenue. The Company records deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2023 and 2022 included customer prepayments of $1.2 million and $1.5 million, respectively. Deferred revenue as of December 31, 2023 and 2022 also included $0.4 million and $0.7 million, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that average price.

Financing and payment. The Company's payment terms vary by the type and location of the customer and products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.

For certain products or services and customer types, the Company may require payment before the products are delivered or services are rendered to the customer.

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Sales commissions are expensed when incurred if the amortization period is one year or less. These costs are recorded in sales and marketing expense in the consolidated statements of operations. If the amortization period exceeds one year, the Company defers the cost of the commission and expenses it over the life of the related sales contract.

Customer and Vendor Concentrations

Customer and vendor concentrations. The Company had one customer that accounted for more than 40% of the Company's consolidated accounts receivable as of December 31, 2023 and 57% as of December 31, 2022. The same customer accounted for approximately 63% of the Company's consolidated net revenues for the year ended December 31, 2023 and 58% for the year ended December 31, 2022. The Company had no customers that accounted for more than 10% of the Company's consolidated net revenues for the year ended December 31, 2021.

The Company currently purchases certain products and critical components of the Company's products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, the Company could be subject to increased costs and substantial delays in the delivery of the Company's products to its customers. Third-party suppliers also manufacture certain products. The Company's inability to have a timely supply of any of these components and products could have a material adverse effect on the Company's business, as well as the Company's financial condition and results of operations.

Research and Development

Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred.

Advertising Expenses

Advertising costs are charged to expense as incurred.

Stock-Based Compensation

The Company accounts for stock-based compensation to employees and directors using the fair value method. The Company recognizes compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. The Company recognizes compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate. To satisfy the exercise of stock options, issuance of restricted stock, or redemption of performance-based restricted stock units, the Company issues new shares rather than purchase shares in the open market.

Income Taxes

The Company follows the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, as well as operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company assesses the realizability of its net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, the Company reduces its net deferred tax assets by a valuation allowance. The realization of the net deferred tax

assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the Company's net operating loss carryforwards.

Foreign Currency Translation

The assets and liabilities of the Company's foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is anti-dilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.


	For the Years Ended December 31,
	2023		2022		2021
Net income (loss)	$	53,655	$	(17,133)	$	(22,998)
Weighted average shares of common stock outstanding:
Basic	73,348		72,505		71,981
Dilutive effect of stock options, restricted stock, and performance stock units	1,041		—		—
Diluted	74,389		72,505		71,981
Earnings per share:
Basic	$	0.73	$	(0.24)	$	(0.32)
Diluted	$	0.72	$	(0.24)	$	(0.32)

Accumulated Other Comprehensive Loss

The Company classifies items of other comprehensive income (loss) by their nature and discloses the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of the Company's consolidated balance sheets.

The Company has defined the Canadian dollar as the functional currency of the Company's Canadian subsidiary, DNAG, and the Company has defined the Euro as the functional currency of the Company's Belgian subsidiary, Novosanis. The results of operations are translated into U.S. dollars, which is the reporting currency of the Company.

Recent Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures. The purpose of the update was to improve financial reporting by requiring disclosures of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this ASU are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted and requires retrospective application to all periods presented in the consolidated financial statements. Management is evaluating the impact on the Company's consolidated financial statements.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. The purpose of the update was to address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and incomes taxes paid information. The amendments in this ASU are effective for annual periods beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. Management is evaluating the impact on the Company's consolidated financial statements.

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ 53,655	$ (17,133)	$ (22,998)
OTHER COMPREHENSIVE LOSS
Currency translation adjustments	3,274	(8,572)	(894)
Unrealized loss on marketable securities	220	214	(86)
COMPREHENSIVE INCOME (LOSS)	$ 57,149	$ (25,491)	$ (23,978)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

Income Taxes - Schedule of Income (Loss) Before Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
United States	$ 61,671	$ (7,111)	$ (60,500)
Foreign	(5,413)	(8,564)	51,208
Income (loss) before income taxes	$ 56,258	$ (15,675)	$ (9,292)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-SubTopic 20
-Topic 940
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481913/940-20-25-1

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 1,216	$ 2,365
Preferred stock, par value (in US dollars per share)	$ 0.000001	$ 0.000001
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in US dollars per share)	$ 0.000001	$ 0.000001
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	73,528,000	72,734,000
Common stock, shares outstanding (in shares)	73,528,000	72,734,000

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Weighted-Average Assumptions for Fair Value Measurement

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


	For the Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2023		2022		2021
Risk-free interest rate(1)	4.23	%	1.65	%	0.47	%
Expected dividend yield	—		—		—
Expected stock price volatility(2)	51	%	50	%	50	%
Expected life of stock options (in years)(2)	5		5		5

(1)Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of the Company's stock options.

(2)Based upon historical experience.

Summary of Company's Stock Option Activity

The following table summarizes the stock option activity under the Stock Plan:


	Options	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding on January 1, 2023	1,758	$	10.25
Granted	617	6.18
Exercised	(44)	6.14
Expired	(89)	9.42
Forfeited	(172)	8.92
Outstanding on December 31, 2023	2,070	$	9.27	6.27	$	—
Vested or expected to vest as of December 31, 2023	2,070	$	9.27	6.27	$	—
Exercisable on December 31, 2023	1,234	$	10.58	4.58	$	—

Schedule of Currently Outstanding and Exercisable Stock Options

The following table summarizes information about stock options outstanding as of December 31, 2023:


Options Outstanding					Options Exercisable
Range of Exercise Prices	Number Outstanding	Weighted- Average Remaining Contractual Term (in years)	Weighted- Average Exercise Price Per Share		Number Exercisable	Weighted- Average Exercise Price Per Share
$5.37 - $8.86	1,422	7.20	$	7.19	628	$	7.58
$8.87 - $13.31	323	3.65	10.78		323	10.78
$14.95 - $22.43	325	4.81	16.83		283	17.02
	2,070	6.27	$	9.27	1,234	$	10.58

Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan

The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan:


	Units	Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2023	2,573	$	6.51
Granted	912	6.05
Vested	(813)	7.13
Forfeited	(151)	8.22
Issued and unvested, December 31, 2023	2,521	$	6.04
Issued and expected to vest, December 31, 2023	2,518	$	6.04

Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan

The following table summarizes PSU activity under the Stock Plan:


	Units	Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2023	715	$	6.86
Granted (1)	548	6.32
Performance adjustment (2)	107	N/A
Vested	(285)	7.17
Forfeited	(94)	6.67
Issued and unvested, December 31, 2023	991	$	6.52
Issued and expected to vest, December 31, 2023	991	$	6.52

(1)Grant activity for all PSUs disclosed at target.

(2)Reflects the performance adjustment based on actual performance measured at the end of the performance period.

Business Segment Information

12 Months Ended

Dec. 31, 2023

Segment Reporting [Abstract]

Business Segment Information

BUSINESS SEGMENT INFORMATION:

The Company is organized on the basis of products and services under a new organizational structure. All products and services reside under the same reporting hierarchy. Historically there was separate management leading the Company's Diagnostics and Molecular Solutions businesses. In February 2023, the Company announced a corporate restructuring to combine the commercial and innovation teams across the Diagnostics and Molecular Solutions segments into one operating segment with sales, marketing, product development and research teams covering all product lines and reporting to a Chief Product Officer. Resources are allocated and performance is assessed on a consolidated basis by the Company's Chief Executive Officer, whom the Company has determined to be its Chief Operating Decision Maker ("CODM"). The CODM reviews the business based on individual product success. Therefore, the Company's historical reportable segments - Diagnostics and Molecular Solutions - are considered one reportable segment and there is no longer is a distinction between Diagnostics and Molecular Solutions, only the Company holistically.

The following table represents total long-lived assets by geographic area:


	December 31,
	2023		2022
United States	$	48,311	$	60,751
Canada	8,777		8,526
Other regions	1,178		1,828
	$	58,266	$	71,105

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//280/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-26

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-34

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

+ Details

Income Taxes - Components of Income Tax Expense (Benefit) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current
Federal	$ 0	$ 0	$ 0
State	1,896,000	955,000	163,000
Foreign	605,000	2,154,000	12,517,000
Total current income tax expense (benefit)	2,501,000	3,109,000	12,680,000
Deferred
Federal	13,570,000	(2,250,000)	(10,318,000)
State	(382,000)	(633,000)	(965,000)
Foreign	(1,867,000)	(2,617,000)	(151,000)
Total deferred income tax expense (benefit)	11,321,000	(5,500,000)	(11,434,000)
Increase (decrease) in valuation allowance	(11,219,000)	3,849,000	12,460,000
Deferred income taxes	102,000	(1,651,000)	1,026,000
Total income tax expense	$ 2,603,000	$ 1,458,000	$ 13,706,000

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Principles of Consolidation and Basis of Presentation

Use of Estimates

Employee Retention Credit

Supplemental Cash Flow Information

The Company received income tax refunds of $4.9 million in 2023, and paid income taxes of $9.4 million and $13.7 million in 2022 and 2021, respectively.

The Company had account receivable write-offs of $0.7 million, $2.3 million, and $0.1 million in 2023, 2022, and 2021, respectively.

As of December 31, 2023, 2022 and 2021, the Company had accruals for purchases of property and equipment of $0.2 million, $0.2 million and $8.2 million, respectively.

Cash Equivalents & Short-Term Investments

The Company had no available-for-sale debt securities as of December 31, 2023. The following is a summary of the Company's available-for-sale securities as of December 31, 2022:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value




December 31, 2022
Guaranteed investment certificates	$	22,109	$	—	$	—	$	22,109
Corporate bonds	4,978		—		(220)		4,758
Total available-for-sale securities	$	27,087	$	—	$	(220)	$	26,867

Fair Value of Financial Instruments

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

measured as Level 1 instruments. Included in cash and cash equivalents at December 31, 2023 was $71.7 million of guaranteed investment certificates which are also measured as Level 1 instruments.

Accounts Receivable

Inventories

Property, Plant and Equipment

Intangible Assets

Impairment of Long-Lived Assets

Goodwill

Revenue

Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, the Company expenses warranty returns as incurred.

The Company records shipping and handling charges billed to the Company's customers as product revenue and the related expense as cost of products sold.

For certain products or services and customer types, the Company may require payment before the products are delivered or services are rendered to the customer.

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Revenues by product. The following table represents total net revenues by product line:


	For the Years Ended December 31,
	2023		2022		2021
COVID-19 (1)	$	257,779	$	243,325	$	76,874
HIV	60,823		38,812		42,144
Molecular Sample Management Solutions (2)	54,274		63,342		72,603
HCV	12,871		13,369		11,783
Risk assessment testing	9,736		10,269		9,678
Molecular Services	4,474		7,296		11,840
Other product and services revenues	2,265		1,634		1,975
Net product and services revenues	402,222		378,047		226,897
Non-product and services revenues (3)	3,250		9,432		6,777
Net revenues	$	405,472	$	387,479	$	233,674

(1) Includes COVID-19 Diagnostics and COVID-19 Molecular Products.

(2) Includes Genomics, Microbiome and Novosanis product revenues.

(3) Non-product and services revenues include funded research and development contracts, royalty income and grant revenues.

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:


	For the Years Ended December 31,
	2023		2022		2021
United States	$	361,660	$	350,206	$	188,383
Europe	8,111		11,536		13,799
Other regions	35,701		25,737		31,492
	$	405,472	$	387,479	$	233,674

Research and Development

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2023, 2022, and 2021, the Company incurred $1.6 million, $4.8 million, and $5.1 million, respectively, in advertising expenses.

Stock-Based Compensation

Income Taxes

assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the Company's net operating loss carryforwards.

Foreign Currency Translation

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in the Company's consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions included in other income in the Company's consolidated statements of operations were $(0.1) million, $1.6 million, and $(0.7) million for the years ended December 31, 2023, 2022, and 2021, respectively.

Earnings (Loss) Per Share


	For the Years Ended December 31,
	2023		2022		2021
Net income (loss)	$	53,655	$	(17,133)	$	(22,998)
Weighted average shares of common stock outstanding:
Basic	73,348		72,505		71,981
Dilutive effect of stock options, restricted stock, and performance stock units	1,041		—		—
Diluted	74,389		72,505		71,981
Earnings per share:
Basic	$	0.73	$	(0.24)	$	(0.32)
Diluted	$	0.72	$	(0.24)	$	(0.32)

For the year ended December 31, 2023, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 1,778 shares were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. For the years ended December 31, 2022, and 2021 outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 436, and 769 shares, respectively, were excluded from the computation of diluted loss per share.

Accumulated Other Comprehensive Loss


	Foreign Currency		Marketable Securities		Total
Balance as of December 31, 2022	$	(18,215)	$	(220)	$	(18,435)
Other comprehensive gain	3,274		220		3,494
Balance as of December 31, 2023	$	(14,941)	$	—	$	(14,941)

Recent Accounting Pronouncements

Immaterial Correction of Errors

In the first quarter of 2023, the Company identified an immaterial error that was corrected in its consolidated financial statements. Inventories, accounts payable and cost of products and services were reduced by $0.5 million, $1.3 million and $0.8 million, respectively, as of and for the year ended December 31, 2022 to correct for the accounting of a vendor rebate earned in 2022. Furthermore, stockholder's equity at December 31, 2022 increased $0.8 million to reflect the reduction in cost of products and services sold. The tax impact of the vendor rebate was negligible. This correction was deemed to be immaterial to the consolidated financial statements as of and for the year ended December 31, 2022. The respective operating activities on the consolidated statement of cash flows for the year ended December 31, 2022 have also been adjusted.

Business Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2023 segment
Segment Reporting [Abstract]
Number of reportable segments	1

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Operating Leases
Right-of-use assets	$ 12,270	$ 10,399
Lease liabilities:
Current lease liabilities	1,577	1,764
Noncurrent lease liabilities	11,162	9,101
Total operating lease liabilities	12,739
Finance Leases
Right-of-use assets	576	1,293
Lease liabilities:
Current lease liabilities	539	1,179
Noncurrent lease liabilities	226	$ 503
Total finance lease liabilities	$ 765
Weighted-average remaining lease term — operating leases	8 years 6 months 3 days	6 years 2 months 26 days
Weighted-average remaining lease term — finance leases	1 year 8 months 15 days	1 year 3 months 29 days
Weighted-average discount rate — operating leases	3.71%	4.06%
Weighted-average discount rate — finance leases	3.45%	3.44%

Stockholders' Equity

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Stockholders' Equity

STOCKHOLDERS’ EQUITY:

Stock-Based Awards

The Company grants stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards.

As of December 31, 2023, 4,581 shares were available for future grants under the Stock Plan.

Under the terms of the Stock Plan, nonqualified stock options may be granted to eligible employees, including the Company's officers at a price not less than 75 percent of the fair market value of a share of common stock on the date of grant. The option term and vesting schedule of such awards may be either unlimited or have a specified period in which to vest and be exercised. To date, options generally have been granted with ten-year exercise periods and an exercise price not less than the fair market value on the date of grant. Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


	For the Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2023		2022		2021
Risk-free interest rate(1)	4.23	%	1.65	%	0.47	%
Expected dividend yield	—		—		—
Expected stock price volatility(2)	51	%	50	%	50	%
Expected life of stock options (in years)(2)	5		5		5

(1)Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of the Company's stock options.

(2)Based upon historical experience.

The weighted-average grant date fair value of stock options granted during the years ended December 31, 2023, 2022, and 2021 was $3.24, $4.15 and $6.14, respectively.

Compensation expense recognized in the financial statements related to stock options was $1.3 million, $1.5 million, and $1.1 million for the years ended December 31, 2023, 2022, and 2021, respectively.

The aggregate intrinsic value of options exercised during the years ended December 31, 2023, 2022, and 2021 (the amount by which the market price of the stock on the date of exercise exceeded the exercise price) was $43.0 thousand, $4.0 thousand, and $130.0 thousand, respectively.

The following table summarizes the stock option activity under the Stock Plan:


	Options	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding on January 1, 2023	1,758	$	10.25
Granted	617	6.18
Exercised	(44)	6.14
Expired	(89)	9.42
Forfeited	(172)	8.92
Outstanding on December 31, 2023	2,070	$	9.27	6.27	$	—
Vested or expected to vest as of December 31, 2023	2,070	$	9.27	6.27	$	—
Exercisable on December 31, 2023	1,234	$	10.58	4.58	$	—

As of December 31, 2023, there was $2.6 million of unrecognized compensation expense related to unvested option awards that is expected to be recognized over a weighted-average period of 2.6 years.

Net cash proceeds from the exercise of stock options were $0.3 million, $0.02 million and $0.2 million for the years ended December 31, 2023, 2022, and 2021, respectively. As a result of the Company's net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises for these periods.

The following table summarizes information about stock options outstanding as of December 31, 2023:


Options Outstanding					Options Exercisable
Range of Exercise Prices	Number Outstanding	Weighted- Average Remaining Contractual Term (in years)	Weighted- Average Exercise Price Per Share		Number Exercisable	Weighted- Average Exercise Price Per Share
$5.37 - $8.86	1,422	7.20	$	7.19	628	$	7.58
$8.87 - $13.31	323	3.65	10.78		323	10.78
$14.95 - $22.43	325	4.81	16.83		283	17.02
	2,070	6.27	$	9.27	1,234	$	10.58

The Stock Plan also permits the Company to grant restricted shares and restricted units of the Company's common stock to eligible employees, including officers, and the Company's outside directors. Generally, these shares or units are nontransferable until vested and are subject to vesting requirements and/or forfeiture, as determined by the Company's Compensation Committee or Board of Directors. The market value of these shares and units at the date of grant is recognized on a straight-line basis over the period during which the vesting restrictions lapse. Compensation cost of $7.6

million, $9.2 million and $4.1 million related to restricted shares was recognized during the years ended December 31, 2023, 2022, and 2021, respectively.

The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan:


	Units	Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2023	2,573	$	6.51
Granted	912	6.05
Vested	(813)	7.13
Forfeited	(151)	8.22
Issued and unvested, December 31, 2023	2,521	$	6.04
Issued and expected to vest, December 31, 2023	2,518	$	6.04

As of December 31, 2023, there was $7.7 million of unrecognized compensation expense related to unvested restricted stock awards and unvested restricted stock units that is expected to be recognized over a weighted average period of 1.5 years.

In connection with the vesting of restricted shares during the years ended December 31, 2023, 2022, and 2021, the Company purchased and immediately retired 262, 241 and 107 shares with aggregate values of $1.4 million, $1.6 million and $1.4 million, respectively, in satisfaction of minimum tax withholding and exercise obligations.

The Company grants performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of certain performance-based metrics during a one-year or three-year period, from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain in the Company's service for three years from the grant date. Performance shares were granted based on the achievement of three-year cumulative revenue metrics with a market-based condition, or a total shareholder return modifier. PSUs are converted into shares of the Company's common stock once vested and the number of shares actually earned at the end of the performance period will vary, based on actual performance, from 0% to 150% of the target number of performance share units granted. Upon grant of the PSUs, the Company recognizes compensation expense related to these awards based on assumptions as to what percentage of each target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate.

Compensation cost of $1.8 million, $0.9 million and $2.7 million related to the PSUs was recognized during the years ended December 31, 2023, 2022, and 2021, respectively.

The following table summarizes PSU activity under the Stock Plan:


	Units	Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2023	715	$	6.86
Granted (1)	548	6.32
Performance adjustment (2)	107	N/A
Vested	(285)	7.17
Forfeited	(94)	6.67
Issued and unvested, December 31, 2023	991	$	6.52
Issued and expected to vest, December 31, 2023	991	$	6.52

(1)Grant activity for all PSUs disclosed at target.

(2)Reflects the performance adjustment based on actual performance measured at the end of the performance period.

As of December 31, 2023, there was $4.4 million of unrecognized compensation expense related to unvested performance stock units that is expected to be recognized over a weighted average period of 1.9 years.

In connection with the vesting of performance stock units during the year ended December 31, 2023, 2022 and 2021, the Company purchased and immediately retired 86, 88, and 46 shares with aggregate values of $0.5 million, $0.6 million and $0.7 million, respectively.

Share Repurchase Program

On August 5, 2008, the Company's Board of Directors approved a share repurchase program pursuant to which the Company is permitted to acquire up to $25.0 million of the Company's outstanding common shares. No shares were purchased and retired in 2023, 2022, and 2021.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS: In January 2024, the Company announced that it is leading the Series B financing and has entered wide-ranging strategic distribution agreements with Sapphiros, a privately held consumer diagnostics portfolio company based in Boston, and certain of its related entities. Through this strategic relationship, the Company expects to be able to offer a more comprehensive range of low-cost diagnostic tests and molecular sample management solutions to its customers globally. On January 2, 2024 and on February 13, 2024, the Company invested $10.0 million and $18.3 million, respectively in Sapphiros for a minority interest, which will be accounted for using the cost basis of accounting. There are future investment commitments of $1.7 million to be paid by June 2024, contingent on certain terms and conditions being met.

Government Capital Contracts - Summary of Government Contracts Balance Included in Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Other current assets:
Total other current assets	$ 2,226	$ 41,569
Other noncurrent assets	1,218	1,087
Accrued expenses and other current liabilities	$ 22,710	25,762
Government Contract
Other current assets:
Billed receivables		0
Unbilled receivables		27,013
Total other current assets		27,013
Other noncurrent assets		0
Accrued expenses and other current liabilities		$ (318)

Leases - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Lessee Disclosure [Abstract]
Operating lease cost	$ 2,407	$ 2,910	$ 2,226
Variable and short-term lease cost	381	521	201
Finance lease cost:
Amortization of right-of use assets	1,091	1,299	900
Interest on lease liabilities	51	94	82
Total finance lease cost	1,142	1,393	982
Total lease cost	$ 3,930	$ 4,824	$ 3,409

Termination Benefits

12 Months Ended

Dec. 31, 2023

Termination Benefits [Abstract]

Termination Benefits

TERMINATION BENEFITS:

During the first and second quarters of 2023, the Company executed a reduction in workforce. This was accounted for pursuant to Accounting Standards Codification ("ASC") 420, Exit or Disposal Cost Obligations.

The expense included in the Company's consolidated statements of operations are as follows:


	For the Year Ended December 31, 2023
Cost of products and services sold	$	369
Research and development	566
Sales and marketing	1,543
General and administrative	787
Total	$	3,265

As of December 31, 2023 the Company had $0.4 million accrued and had paid $2.9 million related to the reduction in workforce.

Stockholders' Equity - Schedule of Currently Outstanding and Exercisable Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Shares outstanding (in shares) \| shares	2,070
Weighted- Average Remaining Contractual Term (in years)	6 years 3 months 7 days
Weighted average exercise price (in US dollars per share)	$ 9.27
Shares exercisable (in shares) \| shares	1,234
Weighted average exercise price (in US dollars per share)	$ 10.58
Range One
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in US dollars per share)	5.37
Upper range limit (in US dollars per share)	$ 8.86
Shares outstanding (in shares) \| shares	1,422
Weighted- Average Remaining Contractual Term (in years)	7 years 2 months 12 days
Weighted average exercise price (in US dollars per share)	$ 7.19
Shares exercisable (in shares) \| shares	628
Weighted average exercise price (in US dollars per share)	$ 7.58
Range Two
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in US dollars per share)	8.87
Upper range limit (in US dollars per share)	$ 13.31
Shares outstanding (in shares) \| shares	323
Weighted- Average Remaining Contractual Term (in years)	3 years 7 months 24 days
Weighted average exercise price (in US dollars per share)	$ 10.78
Shares exercisable (in shares) \| shares	323
Weighted average exercise price (in US dollars per share)	$ 10.78
Range Three
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in US dollars per share)	14.95
Upper range limit (in US dollars per share)	$ 22.43
Shares outstanding (in shares) \| shares	325
Weighted- Average Remaining Contractual Term (in years)	4 years 9 months 21 days
Weighted average exercise price (in US dollars per share)	$ 16.83
Shares exercisable (in shares) \| shares	283
Weighted average exercise price (in US dollars per share)	$ 17.02

Goodwill and Other Intangible Assets - Summary of Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 679
2025	314
2026	213
2027	0
2028	0
Beyond	0
Net	$ 1,206	$ 11,694

Income Taxes - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Contingency [Line Items]
Foreign income tax expense (benefit)		$ 700,000	$ 500,000	$ 13,500,000
State income tax expense (benefit)		1,900,000	1,000,000	200,000
U.S. federal income tax benefits		0	0	0
Foreign earnings repatriated	$ 65,000,000
Gross unrecognized tax benefits		304,000	373,000	$ 805,000	$ 1,172,000
Non Expiring
Income Tax Contingency [Line Items]
Operating loss carryforwards		$ 100,000,000
Canada
Income Tax Contingency [Line Items]
Foreign income tax expense (benefit)			(1,200,000)
Withholding tax paid on the repatriation			$ 1,700,000

Stockholders' Equity - Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan (Detail) - Performance Based Restricted Stock Unit
shares in Thousands

12 Months Ended

Dec. 31, 2023

$ / shares

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]

Beginning balance (in shares)

715

Granted (in shares)

548

^[1]

Performance adjustment (in shares)

107

^[2]

Vested (in shares)

(285)

Forfeited (in shares)

(94)

Ending balance (in shares)

991

Issued and expected to vest (in shares)

991

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

Beginning balance (in US dollars per share) | $ / shares

$ 6.86

Granted (in US dollars per share) | $ / shares

6.32

^[1]

Vested (in US dollars per share) | $ / shares

7.17

Forfeited (in US dollars per share) | $ / shares

6.67

Ending balance (in US dollars per share) | $ / shares

6.52

Issued and expected to vest (in US dollars per share) | $ / shares

$ 6.52

[1]	Grant activity for all PSUs disclosed at target.
[2]	Reflects the performance adjustment based on actual performance measured at the end of the performance period.

Business Segment Information (Tables)

12 Months Ended

Dec. 31, 2023

Segment Reporting [Abstract]

Summary of Total Long-Lived Assets by Geographic Area

The following table represents total long-lived assets by geographic area:


	December 31,
	2023		2022
United States	$	48,311	$	60,751
Canada	8,777		8,526
Other regions	1,178		1,828
	$	58,266	$	71,105

Goodwill and Other Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross	$ 34,854	$ 42,771
Accumulated Amortization	(33,649)	(31,077)
Net	$ 1,206	$ 11,694
Minimum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	5 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	15 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Gross	$ 11,629	$ 14,286
Accumulated Amortization	(11,629)	(11,011)
Net	$ 0	$ 3,275
Patents and product rights
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	5 years	5 years
Gross	$ 7,673	$ 7,620
Accumulated Amortization	(7,102)	(6,615)
Net	571	1,005
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross	10,926	15,478
Accumulated Amortization	(10,926)	(9,940)
Net	$ 0	$ 5,538
Developed technology \| Minimum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	7 years	7 years
Developed technology \| Maximum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross	$ 4,626	$ 5,387
Accumulated Amortization	(3,991)	(3,511)
Net	$ 635	$ 1,876
Trade names \| Minimum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	5 years	5 years
Trade names \| Maximum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	15 years	15 years

Retirement Plans	12 Months Ended
Retirement Plans	Dec. 31, 2023
Retirement Benefits [Abstract]
Retirement Plans	RETIREMENT PLANS: Substantially all of the Company's U.S. employees are eligible to participate in the OraSure Technologies, Inc. 401(k) Plan (the “401(k) Plan”). The 401(k) Plan permits voluntary employee contributions to be excluded from an employee’s current taxable income under provisions of Internal Revenue Code Section 401(k) and the regulations thereunder. The 401(k) Plan also provides for the Company to match employee contributions up to $4 thousand per year. The Company contributed $1.6 million, $1.8 million and $1.3 million to the 401(k) Plan, net of forfeitures, in 2023, 2022, and 2021, respectively. In addition to the Company's 401(k) plan, the Company offers a nonqualified deferred compensation plan to permit eligible directors and highly compensated employees of the Company to defer receipt and taxation of their compensation each year. The Company also may make discretionary contributions to the accounts of the participating employees in any amount either in cash or stock. Participants in the plan may not purchase OraSure stock as an investment vehicle. As of December 31, 2023 and 2022, the value of the assets associated with this plan was $0.8 million and $0.7 million, respectively, and is included in current assets and other assets in the Company's consolidated balance sheets. The Company's obligation related to the deferred compensation plan is included in accrued expenses and other liabilities in the Company's consolidated balance sheets. As of December 31, 2023 and 2022, the Company's total obligation under this plan was $0.8 million and $0.7 million, respectively. Substantially all regular full-time Canadian employees are eligible to participate in the DNA Genotek Registered Retirement Savings Plan (the “RRSP”). The RRSP permits voluntary employee contributions to be excluded from an employee’s current taxable income and receive tax preferred treatment with Canada Revenue Agency. The RRSP also provides for DNAG to match employee contributions up to $4 thousand CAD per year. The Company contributed $0.4 million, $0.5 million and $0.4 million to the RRSP in 2023, 2022, and 2021, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480794/715-70-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480482/715-20-55-17

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//715/tableOfContent

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480266/715-60-50-3

+ Details

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 290,407,000	$ 83,980,000
Short-term investments	0	26,867,000
Accounts receivable, net of allowance for doubtful accounts of $1,216 and $2,365	40,171,000	70,797,000
Inventories	47,614,000	95,704,000
Prepaid expenses	6,041,000	6,273,000
Other current assets	2,226,000	41,569,000
Total current assets	386,459,000	325,190,000
Noncurrent Assets:
Property, plant and equipment, net	45,420,000	59,413,000
Operating right-of-use assets, net	12,270,000	10,399,000
Finance right-of-use assets, net	576,000	1,293,000
Intangible assets, net	1,206,000	11,694,000
Goodwill	35,696,000	35,104,000
Other noncurrent assets	1,218,000	1,087,000
Total noncurrent assets	96,386,000	118,990,000
TOTAL ASSETS	482,845,000	444,180,000
Current Liabilities:
Accounts payable	13,151,000	38,020,000
Deferred revenue	1,559,000	2,273,000
Accrued expenses and other current liabilities	22,710,000	25,762,000
Finance lease liability	539,000	1,179,000
Operating lease liability	1,577,000	1,764,000
Acquisition-related contingent consideration obligation	0	65,000
Total current liabilities	39,536,000	69,063,000
Noncurrent Liabilities:
Finance lease liability	226,000	503,000
Operating lease liability	11,162,000	9,101,000
Acquisition-related contingent consideration obligation	0	99,000
Other noncurrent liabilities	696,000	581,000
Deferred income taxes	554,000	408,000
Total noncurrent liabilities	12,638,000	10,692,000
TOTAL LIABILITIES	52,174,000	79,755,000
Commitments and contingencies (Note 14)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued	0	0
Common stock, par value $.000001, 120,000 shares authorized, 73,528 and 72,734 shares issued and outstanding	0	0
Additional paid-in capital	529,543,000	520,446,000
Accumulated other comprehensive loss	(14,941,000)	(18,435,000)
Accumulated deficit	(83,931,000)	(137,586,000)
Total stockholders' equity	430,671,000	364,425,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 482,845,000	$ 444,180,000

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2023	Feb. 23, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-16537
Entity Registrant Name	ORASURE TECHNOLOGIES, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4370966
Entity Address, Address Line One	220 East First Street
Entity Address, City or Town	Bethlehem
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18015
City Area Code	610
Local Phone Number	882-1820
Title of 12(b) Security	Common Stock, $0.000001 par value per share
Trading Symbol	OSUR
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	true
Document Financial Statement Restatement Recovery Analysis [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 368,293,672
Entity Common Stock, Shares Outstanding		73,796,268
Documents Incorporated by Reference	Part III of this Annual Report on Form 10-K will be incorporated by reference from certain portions of the Registrant's Definitive Proxy Statement for its 2024 Annual Meeting of Shareholders, or will be included in an amendment hereto, to be filed not later than 120 days after the close of the fiscal year ended December 31, 2023. Except with respect to information specifically incorporated by reference in the Annual Report on Form 10-K, the Definitive Proxy Statement is not deemed to be filed as part hereof.
Amendment Flag	false
Entity Central Index Key	0001116463
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY

The Company - Additional Information (Detail) - segment		11 Months Ended
The Company - Additional Information (Detail) - segment	Jan. 31, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of segments	2	1

Commitments and Contingencies - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Estimated penalties to be incurred under minimum purchase commitments, period	3 years
Estimated penalties to be incurred under minimum purchase commitments	$ 1.0

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

PROPERTY, PLANT AND EQUIPMENT:


	December 31,
	2023		2022
Land	$	1,118	$	1,118
Buildings and improvements	34,606		35,582
Machinery and equipment	64,156		60,725
Computer equipment and software	17,739		16,681
Furniture and fixtures	3,748		4,064
Construction in progress	9,196		11,124
	130,563		129,294
Accumulated depreciation	(85,143)		(69,881)
	$	45,420	$	59,413

During the year ended December 31, 2023, the Company determined several manufacturing lines would not be utilized due to changes in forecasted demand for the products the lines are intended to produce. Additionally, the Company elected not to proceed with certain leasehold improvements to its research and development laboratories. As a result of these decisions, the Company determined that the carrying values of the equipment and leasehold improvements are not recoverable and recorded aggregate pre-tax asset impairment charges of $2.3 million for the year ended December 31, 2023.

During the year ended December 31, 2022, the Company determined several manufacturing lines and associated supporting assets would not be utilized due to changes in forecasted demand for the products the lines are intended to produce. As a result of this decision, the Company determined that the carrying values of the equipment and supporting assets were not recoverable and recorded aggregate pre-tax asset impairment charges of $13.5 million for the year ended December 31, 2022. Due to the extremely specialized nature of the equipment and various market data points, the estimated fair value was zero. These charges are reported within loss on impairments in the consolidated statement of operations.

During the second quarter of 2023, the Company shortened the useful lives of machinery and equipment utilized for InteliSwab® production in Thailand. This reduction in useful lives resulted in $6.9 million of accelerated depreciation during the second quarter of 2023, recorded in cost of products and services sold. During the fourth quarter of 2023, the Company shortened the useful lives of leasehold improvements and equipment due a lease termination. This reduction in useful lives resulted in $0.5 million of accelerated depreciation during the fourth quarter of 2023, recorded in cost of products and services sold.

Depreciation expense for 2023, 2022, and 2021 was $17.9 million, $11.7 million, and $7.5 million, respectively.

Goodwill and Other Intangible Assets - Schedule of Goodwill by Operating Segment (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 35,696	$ 35,104	$ 40,279

- Definition

+ References + Details

Inventories (Tables)

12 Months Ended

Dec. 31, 2023

Inventory Disclosure [Abstract]

Schedule of Inventories


	December 31,
	2023		2022
Raw materials	$	20,727	$	42,445
Work in process	1,900		2,335
Finished goods	24,987		50,924
	$	47,614	$	95,704

Business Segment Information - Presentation of Total Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 58,266	$ 71,105
United States
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	48,311	60,751
Canada
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	8,777	8,526
Other regions
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 1,178	$ 1,828

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020		71,738
Beginning balance at Dec. 31, 2020	$ 398,571	$ 0	$ 505,123	$ (9,097)	$ (97,455)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of options (in shares)		33
Common stock issued upon exercise of options	246		246
Vesting of restricted stock and performance stock units (in shares)		451
Purchase and retirement of common shares (in shares)		(153)
Purchase and retirement of common shares	(2,113)		(2,113)
Stock-based compensation	7,807		7,807
Net loss	(22,998)				(22,998)
Currency translation adjustments	(894)			(894)
Unrealized loss on marketable securities	(86)			(86)
Ending balance (in shares) at Dec. 31, 2021		72,069
Ending balance at Dec. 31, 2021	380,533	$ 0	511,063	(10,077)	(120,453)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of options (in shares)		2
Common stock issued upon exercise of options	15		15
Vesting of restricted stock and performance stock units (in shares)		992
Purchase and retirement of common shares (in shares)		(329)
Purchase and retirement of common shares	(2,254)		(2,254)
Stock-based compensation	11,622		11,622
Net loss	(17,133)				(17,133)
Currency translation adjustments	(8,572)			(8,572)
Unrealized loss on marketable securities	214			214
Ending balance (in shares) at Dec. 31, 2022		72,734
Ending balance at Dec. 31, 2022	$ 364,425	$ 0	520,446	(18,435)	(137,586)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of options (in shares)	44	44
Common stock issued upon exercise of options	$ 269		269
Vesting of restricted stock and performance stock units (in shares)		1,098
Purchase and retirement of common shares (in shares)		(348)
Purchase and retirement of common shares	(1,901)		(1,901)
Stock-based compensation	10,729		10,729
Net loss	53,655				53,655
Currency translation adjustments	3,274			3,274
Unrealized loss on marketable securities	220			220
Ending balance (in shares) at Dec. 31, 2023		73,528
Ending balance at Dec. 31, 2023	$ 430,671	$ 0	$ 529,543	$ (14,941)	$ (83,931)

Inventories

12 Months Ended

Dec. 31, 2023

Inventory Disclosure [Abstract]

Inventories

INVENTORIES:


	December 31,
	2023		2022
Raw materials	$	20,727	$	42,445
Work in process	1,900		2,335
Finished goods	24,987		50,924
	$	47,614	$	95,704

During the years ended December 31, 2023, 2022, and 2021, the Company recorded adjustments to inventory which had a cost of $8.9 million, $15.6 million, and $13.4 million, respectively. The adjustments in 2021 included a write-off of $3.0 million of COVID-19 antibody inventory, which the Company did not believe it could sell as a result of the decision to no longer pursue an emergency use authorization for the enzyme-linked immunosorbent assay ("ELISA") antibody test. Additionally, a significant portion of the Company's 2022 and 2021 adjustments were related to production and tech-transfer issues associated with the Company's COVID-19 rapid test. The year ended December 31, 2023 adjustments were primarily related to reduction in COVID-19 demand and the need to reserve for excess inventory levels.

Government Capital Contracts (Tables)

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Government Contracts Balance Included in Consolidated Balance Sheet

The balances corresponding to government contracts included in the Company's consolidated balance sheet are as follows:


	December 31,
		2022
Other current assets:
Billed receivables		$	—
Unbilled receivables		27,013
Total other current assets		27,013
Other noncurrent assets		—
Accrued expenses and other current liabilities		$	(318)

Summary of Government Contracts Balances Included In Consolidated Statements Of Cashflows

The activity corresponding to the government contracts included in the Company's consolidated statements of cash flows is as follows:


	December 31,
	2023		2022
Cost of assets, cumulative	$	86,993	$	83,359
Reduction for funding earned to date, not yet received	—		(22,497)
Reduction for funding received to date	(86,993)		(60,862)
Total property, plant and equipment, net	$	—	$	—

Income Taxes - Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Statutory U.S. federal income tax rate	21.00%	21.00%	21.00%
Nondeductible executive compensation	0.50%	(5.80%)	(6.10%)
Impact of stock-based payment awards	(0.30%)	(5.10%)	(3.30%)
Tax effect of foreign items	(0.40%)	(6.00%)	(30.80%)
State income taxes, net of federal benefit	2.00%	(0.80%)	6.80%
U.S. and foreign tax credits	1.30%	3.70%	2.50%
Nondeductible expenses and other	0.90%	8.70%	(4.00%)
Change in valuation allowance, federal and state	(20.40%)	(25.00%)	(133.60%)
Effective tax rate	4.60%	(9.30%)	(147.50%)

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 1,863	$ 2,209	$ 3,733
Operating cash flows from financing leases	51	94	82
Financing cash flows from financing leases	1,345	1,381	686
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations	4,363	3,963	6,480
Right-of-use assets obtained in exchange for finance lease obligations	$ 334	$ 117	$ 2,074

Government Capital Contracts - Summary of Government Contracts Included in Statements of Cash Flows (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of assets, cumulative	$ 130,563	$ 129,294
Total property, plant and equipment, net	45,420	59,413
Government Contract
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of assets, cumulative	86,993	83,359
Reduction for funding earned to date, not yet received	0	(22,497)
Reduction for funding received to date	(86,993)	(60,862)
Total property, plant and equipment, net	$ 0	$ 0

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment


	December 31,
	2023		2022
Land	$	1,118	$	1,118
Buildings and improvements	34,606		35,582
Machinery and equipment	64,156		60,725
Computer equipment and software	17,739		16,681
Furniture and fixtures	3,748		4,064
Construction in progress	9,196		11,124
	130,563		129,294
Accumulated depreciation	(85,143)		(69,881)
	$	45,420	$	59,413

Transition Costs	12 Months Ended
Transition Costs	Dec. 31, 2023
Transition Costs [Abstract]
Transition Costs	TRANSITION COSTS On December 31, 2021, the Company's Board of Directors approved the termination of Stephen S. Tang, the Company’s President and Chief Executive Officer, without cause under his existing employment agreement with the Company, with such termination effective as of March 31, 2022. On January 2, 2022, Dr. Tang and the Company entered into a Transition Agreement providing for the terms of the cessation of Dr. Tang’s employment with the Company, including the cessation of his service as President and Chief Executive Officer of the Company and as a member of the Board. Under the Transition Agreement, Dr. Tang’s service to the Company in all capacities ended on March 31, 2022. Pursuant to the Transition Agreement, Dr. Tang received severance of $1.6 million, which was accrued in the consolidated financial statements at December 31, 2021 and paid in April 2022. Additionally, in accordance with his Transition Agreement, certain of his unvested time-vesting restricted stock awards and unvested PSUs that were outstanding at March 31, 2022 vested on April 8, 2022. His remaining unvested time-vesting restricted stock awards and PSUs were forfeited on March 31, 2022. These payments, rights and benefits are substantially similar to the severance benefits contemplated by his previous employment agreement in respect to a termination without cause thereunder. In aggregate, the Company recognized $1.5 million of expense in relation to Dr. Tang's stock compensation for the year ended December 31, 2022.

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 20,727	$ 42,445
Work in process	1,900	2,335
Finished goods	24,987	50,924
Total	$ 47,614	$ 95,704

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 130,563	$ 129,294
Accumulated depreciation	(85,143)	(69,881)
Total property, plant and equipment, net	45,420	59,413
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,118	1,118
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	34,606	35,582
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	64,156	60,725
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	17,739	16,681
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,748	4,064
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 9,196	$ 11,124

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

Changes in goodwill are as follows:


	December 31,
	2023		2022
Balance as of January 1	$	35,104	$	40,279
Impairment	—		(3,604)
Change related to foreign currency translation	592		(1,571)
Balance as of December 31	$	35,696	$	35,104

Summary of Intangible Assets

Intangible assets consist of the following:


		December 31, 2023
	Amortization Period (Years)	Gross		Accumulated Amortization		Net
Customer relationships	10	$	11,629	$	(11,629)	$	—
Patents and product rights	5	7,673		(7,102)		571
Developed technology	7-10	10,926		(10,926)		—
Trade names	5-15	4,626		(3,991)		635
		$	34,854	$	(33,649)	$	1,206


		December 31, 2022
	Amortization Period (Years)	Gross		Accumulated Amortization		Net
Customer relationships	10	$	14,286	$	(11,011)	$	3,275
Patents and product rights	5	7,620		(6,615)		1,005
Developed technology	7-10	15,478		(9,940)		5,538
Trade names	5-15	5,387		(3,511)		1,876
		$	42,771	$	(31,077)	$	11,694

Summary of Amortization Expense

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:


2024	$	679
2025	314
2026	213
2027	—
2028	—
Beyond	—
	$	1,206

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

+ Details

Summary of Significant Accounting Policies - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation Of Revenue [Line Items]
Net revenues	$ 405,472	$ 387,479	$ 233,674
Product and Services Revenues
Disaggregation Of Revenue [Line Items]
Net revenues	402,222	378,047	226,897
Product and Services Revenues \| COVID-19 (1)
Disaggregation Of Revenue [Line Items]
Net revenues	257,779	243,325	76,874
Product and Services Revenues \| HIV
Disaggregation Of Revenue [Line Items]
Net revenues	60,823	38,812	42,144
Product and Services Revenues \| Molecular Sample Management Solutions (2)
Disaggregation Of Revenue [Line Items]
Net revenues	54,274	63,342	72,603
Product and Services Revenues \| HCV
Disaggregation Of Revenue [Line Items]
Net revenues	12,871	13,369	11,783
Product and Services Revenues \| Risk assessment testing
Disaggregation Of Revenue [Line Items]
Net revenues	9,736	10,269	9,678
Product and Services Revenues \| Molecular Services
Disaggregation Of Revenue [Line Items]
Net revenues	4,474	7,296	11,840
Product and Services Revenues \| Other product and services revenues
Disaggregation Of Revenue [Line Items]
Net revenues	2,265	1,634	1,975
Other
Disaggregation Of Revenue [Line Items]
Net revenues	405,472	387,479	233,674
Other \| Non-product and services revenues
Disaggregation Of Revenue [Line Items]
Net revenues	$ 3,250	$ 9,432	$ 6,777

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities


	December 31,
	2023		2022
Payroll and related benefits	$	14,654	$	14,103
Professional fees	2,827		4,685
Sales tax payable	1,245		1,519
Other	3,984		5,455
	$	22,710	$	25,762

Inventories - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Inventory [Line Items]
Inventory adjustments	$ 8.9	$ 15.6	$ 13.4
COVID-19 Antibody
Inventory [Line Items]
Inventory adjustments			$ 3.0

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 27,087
Gross Unrealized Gains	0
Gross Unrealized Losses	(220)
Fair Value	26,867
Guaranteed investment certificates
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	22,109
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Fair Value	22,109
Corporate bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	4,978
Gross Unrealized Gains	0
Gross Unrealized Losses	(220)
Fair Value	$ 4,758

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

+ Details

Leases - Summary of Lease Term and Discount Rate (Detail)	Dec. 31, 2023	Dec. 31, 2022
Weighted Average Remaining Lease Term
Weighted-average remaining lease term — operating leases	8 years 6 months 3 days	6 years 2 months 26 days
Weighted-average remaining lease term — finance leases	1 year 8 months 15 days	1 year 3 months 29 days
Weighted Average Discount Rate
Weighted-average discount rate — operating leases	3.71%	4.06%
Weighted-average discount rate — finance leases	3.45%	3.44%

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance (in shares) \| shares	1,758
Granted (in shares) \| shares	617
Exercised (in shares) \| shares	(44)
Expired (in shares) \| shares	(89)
Forfeited (in shares) \| shares	(172)
Ending balance (in shares) \| shares	2,070
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Vested or expected to vest (in shares) \| shares	2,070
Exercisable (in shares) \| shares	1,234
Beginning balance (in US dollars per share) \| $ / shares	$ 10.25
Granted (in US dollars per share) \| $ / shares	6.18
Exercised (in US dollars per share) \| $ / shares	6.14
Expired (in US dollars per share) \| $ / shares	9.42
Forfeited (in US dollars per share) \| $ / shares	8.92
Ending balance (in US dollars per share) \| $ / shares	9.27
Vested or expected to vest (in US dollars per share) \| $ / shares	9.27
Exercisable (in US dollars per share) \| $ / shares	$ 10.58
Weighted-average remaining contractual term, outstanding	6 years 3 months 7 days
Weighted-average remaining contractual term, vested or expected to vest	6 years 3 months 7 days
Weighted-average remaining contractual term, exercisable	4 years 6 months 29 days
Aggregate intrinsic value, outstanding \| $	$ 0
Aggregate intrinsic value, vested or expected to vest \| $	0
Aggregate intrinsic value, exercisable \| $	$ 0